Fig. 2
The relative dose intensity of oxaliplatin (RDI-O) ≥60 vs < 60% and early recurrence in the whole group within 12, 18 and 36 months
Fig. 2 | BMC Cancer
The relative dose intensity of oxaliplatin (RDI-O) ≥60 vs < 60% and early recurrence in the whole group within 12, 18 and 36 months